Product image of Mivacron (Mivacurium) supplied by GNH India

Mivacron

Active Ingredient:
Mivacurium
Origin:
EU

Mivacron (Mivacurium)

Mivacurium, the active ingredient in Mivacron, is a non‑depolarizing neuromuscular blocking agent presented as an injectable solution for intravenous use. It produces skeletal muscle relaxation by competitively antagonising acetylcholine at nicotinic receptors, and is employed to facilitate endotracheal intubation, to maintain muscle relaxation during surgical procedures, and as an adjunct to mechanical ventilation in intensive‑care settings.

GNH India supplies Mivacron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies, clinics and research institutions worldwide.

Manufacturer / TM Owner

Aspen Pharma Trading Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mivacurium is a non‑depolarizing neuromuscular blocker used in peri‑operative care to produce skeletal muscle relaxation.

  • Facilitation of endotracheal intubation: enables rapid and controlled airway placement.
  • Muscle relaxation during surgery: provides a stable, flaccid field for operative manipulation.
  • Adjunct to mechanical ventilation: supports prolonged ventilation by preventing spontaneous breathing efforts.

How It Works

  • Mivacurium competitively binds to nicotinic acetylcholine receptors at the motor end‑plate of the neuromuscular junction, preventing acetylcholine from activating the ion channel. This blockade inhibits depolarisation of the muscle fiber membrane, resulting in reversible skeletal muscle relaxation without depolarising the motor end‑plate.

Side Effects

Mivacurium may cause a range of adverse reactions, which are categorised by frequency.

Common Side Effects

  • Flushing: transient redness of the skin.
  • Mild hypotension: temporary drop in blood pressure.
  • Tachycardia: increased heart rate.
  • Pruritus: itching sensation.
  • Nausea: feeling of sickness.
  • Urticaria: hives or skin rash.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate treatment.
  • Severe hypotension: marked blood‑pressure fall that may need vasopressor support.
  • Bronchospasm: airway constriction causing breathing difficulty.
  • Prolonged neuromuscular blockade: extended muscle paralysis beyond intended duration.
  • Cardiac arrhythmias: irregular heart rhythms.
  • Hyperkalemia: elevated serum potassium levels.

Precautions & Warnings

When using Mivacron, clinicians should observe several safety measures.

  • Assess neuromuscular function: monitor train‑of‑four ratio during administration.
  • Avoid in patients with known hypersensitivity to mivacurium or related benzylisoquinolinium compounds.
  • Use with caution in hepatic or renal impairment: altered drug clearance may occur.
  • Consider dose reduction in the elderly: increased sensitivity to blockade.
  • Monitor for histamine‑mediated reactions: be prepared to treat hypotension or bronchospasm.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Mivacron can interact with other agents that affect neuromuscular transmission.

Major Interactions (Avoid)

  • Aminoglycoside antibiotics: potentiate neuromuscular blockade.
  • Magnesium sulfate: enhances blockade and may cause prolonged paralysis.
  • Lithium: increases sensitivity to muscle relaxants.

Moderate Interactions (Monitor Closely):\n- Inhalational anesthetics: additive effect on muscle relaxation.

  • Volatile agents (e.g., sevoflurane): may prolong duration of action.
  • Beta‑agonists: may reduce the depth of blockade, requiring dose adjustment.

Frequently Asked Questions

Mivacron contains the neuromuscular blocking agent mivacurium and is used to facilitate endotracheal intubation, to provide skeletal muscle relaxation during surgical procedures, and as an adjunct to mechanical ventilation in intensive‑care settings.

Mivacurium acts by competitively antagonising acetylcholine at nicotinic receptors of the motor end‑plate. This prevents depolarisation of the muscle membrane, producing a reversible, dose‑dependent relaxation of skeletal muscle.

The dose of Mivacron is determined by the prescribing clinician based on the patient’s age, weight, underlying medical conditions, and the specific clinical situation such as the need for intubation or surgical relaxation.

Mivacron’s pregnancy category is listed as unknown. It should only be used during pregnancy or lactation when the potential benefit justifies any possible risk to the fetus or infant, and under close medical supervision.

To order Mivacron, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Mivacron is a short‑acting, non‑depolarizing agent that is rapidly hydrolysed by plasma cholinesterase, giving a quicker recovery than longer‑acting agents such as rocuronium or vecuronium. Its onset is comparable to other benzylisoquinolinium compounds, but it may cause more histamine release, leading to flushing or hypotension.

Mivacron should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the vial. Before use, allow the solution to reach room temperature and inspect for particulate matter or discoloration.

Mivacron is supplied as an injectable solution for intravenous use. It is administered as a bolus dose for rapid onset, followed by optional continuous infusion if prolonged muscle relaxation is required, with neuromuscular monitoring throughout the procedure.

Serious risks include anaphylaxis, severe hypotension, bronchospasm, prolonged neuromuscular blockade, cardiac arrhythmias, and hyperkalemia. Prompt recognition and treatment of these events are essential, and patients should be monitored continuously during and after administration.

Mivacron is contraindicated in patients with a known hypersensitivity to mivacurium or other benzylisoquinolinium compounds. Caution is also advised in individuals with severe hepatic or renal impairment, myasthenia gravis, or those receiving drugs that markedly potentiate neuromuscular blockade.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mivacurium

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT